Search

Your search keyword '"Casasnovas, R."' showing total 150 results
Start Over Author "Casasnovas, R."
150 results on '"Casasnovas, R."'

3. RADIOMICS REFLECTING BOTH TUMOR AND HOST FEATURES IMPROVES OUTCOME PREDICTION IN FOLLICULAR LYMPHOMA

Author

Rebaud, L., primary, Capobianco, N., additional, Spottiswoode, B., additional, Cottereau, A., additional, Trotman, J., additional, Feugier, P., additional, Nastoupil, L. J., additional, Bachy, E., additional, Flinn, I. W., additional, Haioun, C., additional, Ysebaert, L., additional, Bartlett, N. L., additional, Tilly, H., additional, Casasnovas, R., additional, Ricci, R., additional, Portugues, C., additional, Meignan, M., additional, Morschhauser, F., additional, and Buvat, I., additional

Published
2023
Full Text
View/download PDF

4. Patient‐ versus clinician‐reported symptoms in the POLARIX study

Author

Thompson, C. A., primary, Mehta‐Shah, N., additional, Flowers, C., additional, Salles, G., additional, Tilly, H., additional, Chua, N., additional, Casasnovas, R., additional, Miall, F., additional, Kim, T. M., additional, Tsai, C., additional, Nasta, S., additional, Lee, S. T., additional, Craine, V., additional, Campinha‐Bacote, A., additional, Hirata, J., additional, Lee, C., additional, Sugidono, M., additional, and Friedberg, J. W., additional

Published
2023
Full Text
View/download PDF

5. Efficacy of anti‐PD1 therapy in relapsed or refractory NK/T cell lymphoma: a matched cohort analysis from the LYSA

Author

Marouf, A., primary, Chaubard, S., additional, Michot, J., additional, Liévin, R., additional, Rossignol, J., additional, Golfier, C., additional, Allangba, O., additional, Philippe, L., additional, Tessoulin, B., additional, Chauchet, A., additional, Deau, B., additional, Oberic, L., additional, Vargaftig, J., additional, Moignet, A., additional, Clavert, A., additional, Dulery, R., additional, Brisou, G., additional, Tardy, S., additional, Fataccioli, V., additional, Houot, R., additional, Casasnovas, R., additional, Thieblemont, C., additional, Ghesquières, H., additional, Carras, S., additional, Le Gouill, S., additional, Cartron, G., additional, Marabelle, A., additional, Tournilhac, O., additional, Damaj, G., additional, Gaulard, P., additional, De Leval, L., additional, Lemonnier, F., additional, Bachy, E., additional, Hermine, O., additional, Couronné, L., additional, and Jaccard, A., additional

Published
2023
Full Text
View/download PDF

6. Tandem haematopoietic stem cell transplantation versus single cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSA

Author

Marouf, A., primary, Molinari, N., additional, Sibon, D., additional, Cottereau, A. S., additional, Kanoun, S., additional, Antoine, C., additional, Debureaux, P. E., additional, Cavalieri, D., additional, Fornecker, L. M., additional, Casasnovas, R. O., additional, Herbaux, C., additional, Amorim, S., additional, Rossi, C., additional, Bouscary, D., additional, Brice, P., additional, Ghesquieres, H., additional, Tamburini, J., additional, and Deau, B., additional

Published
2023
Full Text
View/download PDF

9. Tandem versus single haematopoietic stem cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSA.

Author

Marouf, A., Molinari, N., Sibon, D., Cottereau, A. S., Kanoun, S., Antoine, C., Debureaux, P. E., Cavalieri, D., Fornecker, L. M., Casasnovas, R. O., Herbaux, C., Amorim, S., Rossi, C., Bouscary, D., Brice, P., Ghesquieres, H., Tamburini, J., and Deau, B.

Subjects
HEMATOPOIETIC stem cells, STEM cell transplantation, HODGKIN'S disease, COHORT analysis, SURVIVAL rate
Abstract

Summary: Autologous hematopoietic stem cell transplant (ASCT) is the standard curative treatment for patients with high‐risk relapsed/refractory Hodgkin lymphoma (R/R HL). The AETHERA study showed survival gain with Brentuximab Vedotin (BV) maintenance after ASCT in BV‐naive patients, which was recently confirmed in the retrospective AMAHRELIS cohort, including a majority of BV‐exposed patients. However, this approach has not been compared to intensive tandem auto/auto or auto/allo transplant strategies, which were used before BV approval. Here, we matched BV maintenance (AMAHRELIS) and tandem SCT (HR2009) cohorts, and observed that BV maintenance was associated with better survival outcome in patients with HR R/R HL. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

10. Database of spatial distribution of non indigenous species in Spanish marine waters

Author

Carbonell, A. (Ana), Png-Gonzalez, L. (Lydia), Falcón, J.M. (Jesús), Comas-González, R. (Robert), Follana, G. (Guillermo), Cefali, M.E. (María Elena), Calvo-Manazza, M. (Matías), Díaz-Tapia, P. (Pilar), Rueda, J.L. (José Luis), Mateo-Ramírez, Á. (Ángel), Urra, J. (Javier), Velasco, E.M. (Eva María), Carbonell, A., Arroyo, N.L. (Nina Larissa), Ríos, P. (Pilar), Valls-Mir, M. (María), Guijarro, B. (Beatriz), Esteban-Acón, A. (Antonio), García-Ruiz, C. (Cristina), Díaz, D. (David), Real, E. (Enric), Vázquez-Luis, M. (Maite), Ruiz-Fernández, J.M. (Juan Manuel), González-Porto, M. (Marcos), Tello-Antón, M.O. (María Olvido), Bruque-Carmona, G. (Gerardo), Mata-Chacón, D. (Dulce), Cabezuelo-Hernández, A. (Alberto), Agudo-Bravo, L.M. (Luis Miguel), Ramos, A., Ros, M., Monterroso, O., Zurita, M.N., Herrera, R., Casasnovas, R., Racionero, C., De la Rosa, J., Vivas, M.S., Serradilla, J., Gofas, S., López García, E., Ballesteros-Fernández, E. (Enrique), Bárbara, I., Bañón, R. (Rafael), Altamirano, M., Izquierdo-Muñoz, A., Nash, F.T., Arias, A., Britó, A., García-Raso, E., and Sánchez-Conde, F.J. (Francisco Javier)

Abstract

Research in marine Spanish waters are focused on several actions to achieve an effectively management on protected areas, with the active participation of the stakeholders and research as basic tools for decision-making. Among these actions, there is one about the knowledge and control on NIS. One of its objectives is the creation of NIS factsheets, which are going to be added to the National Marine Biodiversity Geographical System (GIS) providing complementary information about taxonomic classification, common names, taxonomic synonyms, species illustrations, identification morphological characters, habitat in the native and introduced regions, biological and ecological traits, GenBank DNA sequences, world distribution, first record and evolution in the introduced areas, likely pathways of introduction, effects in the habitats and interaction with native species, and potential management measures to apply. The database will also provide data for (1) the European online platforms, (2) the environmental assessment for the Descriptor 2 (D2-NIS) of the EU Marine Strategy Framework Directive (MSFD), as well as (3) supporting decisions made by stakeholders. It is the result of extensive collaboration among scientist, manager’s and citizen science in the Spanish North-Atlantic, South-Atlantic, Gibraltar Strait-Alboran, Levantine-Balearic and Canary Islands marine divisions, providing an updated overview of the spatial distribution of relevant extended and invasive NIS of recent and established NIS introduced by maritime transport and aquaculture pathways, as well as on cryptogenic or native species in expansion due to the climatic water warming trend.

Published
2022

11. The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study

Author

Zijlstra, JM, Follows, G, Casasnovas, R-O, Vermaat, JSP, Kalakonda, N, Choquet, S, Hill, B, Thieblemont, C, Cavallo, F, Cruz, FDL, Kuruvilla, J, Hamad, N, Jaeger, U, Caimi, P, Gurion, R, Warzocha, K, Bakhshi, S, Sancho, J-M, Schuster, M, Egyed, M, Offner, F, Vassilakopoulos, TP, Samal, P, Ku, M, Xu, J, Corona, K, Chamoun, K, Shah, J, Canales, M, Maerevoet, M, Zijlstra, JM, Follows, G, Casasnovas, R-O, Vermaat, JSP, Kalakonda, N, Choquet, S, Hill, B, Thieblemont, C, Cavallo, F, Cruz, FDL, Kuruvilla, J, Hamad, N, Jaeger, U, Caimi, P, Gurion, R, Warzocha, K, Bakhshi, S, Sancho, J-M, Schuster, M, Egyed, M, Offner, F, Vassilakopoulos, TP, Samal, P, Ku, M, Xu, J, Corona, K, Chamoun, K, Shah, J, Canales, M, and Maerevoet, M

Abstract

Selinexor, an oral selective inhibitor of nuclear export, was evaluated in the Phase 2b SADAL study in patients with diffuse large B-cell lymphoma (DLBCL) who previously received two to five prior systemic regimens. In post hoc analyses, we analyzed several categories of patient characteristics (age, renal function, DLBCL subtype, absolute lymphocyte count, transplant status, number of prior lines of therapy, refractory status, Ann Arbor disease stage, and lactate dehydrogenase) at baseline, i.e., during screening procedures, to determine their potential contributions to the efficacy (overall response rate [ORR], duration of response [DOR], overall survival [OS]) and tolerability of selinexor. Across most categories of characteristics, no significant difference was observed in ORR or DOR. OS was significantly longer for patients < 65 vs. ≥ 65 years, and for those with lymphocyte counts ≥ 1000/µL vs. < 1000/µL or lactate dehydrogenase ≤ ULN vs. > ULN. The most common adverse events (AEs) across the characteristics were thrombocytopenia and nausea, and similar rates of grade 3 AEs and serious AEs were observed. With its oral administration, novel mechanism of action, and consistency in responses in heavily pretreated patients, selinexor may help to address an important unmet clinical need in the treatment of DLBCL.

Published
2022

12. Database of spatial distribution of non indigenous species in Spanish marine waters

Author

Carbonell, Ana, Png-González, Lydia, Falcón, Jesús, Comas-González, Robert, Follana, Guillermo, Cefali, María Elena, Calvo-Manazza, Matías, Díaz-Tapia, Pilar, Rueda, José Luis, Mateo-Ramírez, Ángel, Urra, Javier, Velasco, Eva María, Arroyo, Nina Larissa, Ríos, Pilar, Valls-Mir, María, Guijarro, Beatriz, Esteban-Acón, Antonio, García-Ruiz, Cristina, Díaz Viñolas, David, Real, Enric, Vázquez-Luis, Maite, Ruiz-Fernández, Juan Manuel, González-Porto, Marcos, Tello-Antón, María Olvido, Bruque-Carmona, Gerardo, Mata-Chacón, Dulce, Cabezuelo-Hernández, Alberto, Agudo-Bravo, Luis Miguel, Ramos, Ana, Ros, M., Monterroso, O., Zurita, M.N., Herrera, R., Casasnovas, R., Racionero, C., De la Rosa, J., Vivas-Salvador, Miguel, Serradilla, J., Gofas, S., López García, E., Ballesteros-Fernández, Enrique, Bárbara, I., Bañón, Rafael, Altamirano, M., Izquierdo-Muñoz, A., Nash, F.T., Arias, A., Britó, A., García-Raso, E., Sánchez-Conde, Francisco Javier, Carbonell, Ana, Png-González, Lydia, Falcón, Jesús, Comas-González, Robert, Follana, Guillermo, Cefali, María Elena, Calvo-Manazza, Matías, Díaz-Tapia, Pilar, Rueda, José Luis, Mateo-Ramírez, Ángel, Urra, Javier, Velasco, Eva María, Arroyo, Nina Larissa, Ríos, Pilar, Valls-Mir, María, Guijarro, Beatriz, Esteban-Acón, Antonio, García-Ruiz, Cristina, Díaz Viñolas, David, Real, Enric, Vázquez-Luis, Maite, Ruiz-Fernández, Juan Manuel, González-Porto, Marcos, Tello-Antón, María Olvido, Bruque-Carmona, Gerardo, Mata-Chacón, Dulce, Cabezuelo-Hernández, Alberto, Agudo-Bravo, Luis Miguel, Ramos, Ana, Ros, M., Monterroso, O., Zurita, M.N., Herrera, R., Casasnovas, R., Racionero, C., De la Rosa, J., Vivas-Salvador, Miguel, Serradilla, J., Gofas, S., López García, E., Ballesteros-Fernández, Enrique, Bárbara, I., Bañón, Rafael, Altamirano, M., Izquierdo-Muñoz, A., Nash, F.T., Arias, A., Britó, A., García-Raso, E., and Sánchez-Conde, Francisco Javier

Abstract

Research in marine Spanish waters are focused on several actions to achieve an effectively management on protected areas, with the active participation of the stakeholders and research as basic tools for decision-making. Among these actions, there is one about the knowledge and control on NIS. One of its objectives is the creation of NIS factsheets, which are going to be added to the National Marine Biodiversity Geographical System (GIS) providing complementary information about taxonomic classification, common names, taxonomic synonyms, species illustrations, identification morphological characters, habitat in the native and introduced regions, biological and ecological traits, GenBank DNA sequences, world distribution, first record and evolution in the introduced areas, likely pathways of introduction, effects in the habitats and interaction with native species, and potential management measures to apply. The database will also provide data for (1) the European online platforms, (2) the environmental assessment for the Descriptor 2 (D2-NIS) of the EU Marine Strategy Framework Directive (MSFD), as well as (3) supporting decisions made by stakeholders. It is the result of extensive collaboration among scientist, manager’s and citizen science in the Spanish North-Atlantic, South-Atlantic, Gibraltar Strait-Alboran, Levantine-Balearic and Canary Islands marine divisions, providing an updated overview of the spatial distribution of relevant extended and invasive NIS of recent and established NIS introduced by maritime transport and aquaculture pathways, as well as on cryptogenic or native species in expansion due to the climatic water warming trend.

Published
2022

13. S210: CAR T-CELLS ASSOCIATED ACUTE TOXICITY IN B-CELL NON-HODGKIN LYMPHOMA: REAL-WORLD STUDY FROM THE DESCAR-T REGISTRY

Author

SESQUES, P., primary, DI BLASI, R., additional, LE GOUILL, S., additional, CARTRON, G., additional, MANSON, G., additional, BEAUVAIS, D., additional, LE BRAS, F., additional, GROS, F. X., additional, CHOQUET, S., additional, BORIES, P., additional, RUBIO, M. T., additional, CASASNOVAS, R. O., additional, BOUNAIX, L., additional, MOHTY, M., additional, JORIS, M., additional, ABRAHAM, J., additional, CASTILLA LLORENTE, C., additional, LOSCHI, M., additional, CARRAS, S., additional, CHAUCHET, A., additional, DRIEU LA ROCHELLE, L., additional, ZERBIT, J., additional, HERMINE, O., additional, GUIDEZ, S., additional, GASTINNE, T., additional, TUDESQ, J. J., additional, FOGARTY, P., additional, BROUSSAIS, F., additional, MORSCHHAUSER, F., additional, HOUOT, R., additional, THIEBLEMONT, C., additional, and BACHY, E., additional

Published
2022
Full Text
View/download PDF

14. S260: A MATCHED COMPARISON OF TISAGENLECLEUCEL AND AXICABTAGENE CILOLEUCEL CAR T CELLS IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A REAL-LIFE LYSA STUDY FROM THE FRENCH DESCAR-T REGISTRY

Author

Bachy, E., primary, Le Gouill, S., additional, Sesques, P., additional, Di Blasi, R., additional, Guillaume, M., additional, Cartron, G., additional, Beauvais, D., additional, Roulin, L., additional, Gros, F. X., additional, Rubio, M. T., additional, Bories, P., additional, Bay, J. O., additional, Castilla Llorente, C., additional, Choquet, S., additional, Casasnovas, R.-O., additional, Mothy, M., additional, Guidez, S., additional, Joris, M., additional, Loschi, M., additional, Carras, S., additional, Abraham, J., additional, Chauchet, A., additional, Drieu La Rochelle, L., additional, Zerbit, J., additional, Hermine, O., additional, Gastinne, T., additional, Tudesq, J. J., additional, Gat, E., additional, Broussais, F., additional, Thieblemont, C., additional, Houot, R., additional, and Morschhauser, F., additional

Published
2022
Full Text
View/download PDF

15. S201: CAMIDANLUMAB TESIRINE: UPDATED EFFICACY AND SAFETY IN AN OPEN-LABEL, MULTICENTER, PHASE 2 STUDY OF PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL)

Author

Carlo-Stella, C., primary, Ansell, S., additional, Zinzani, P. L, additional, Radford, J., additional, Maddocks, K., additional, Pinto, A., additional, Collins, G. P., additional, Bachanova, V., additional, Bartlett, N., additional, Bence-Bruckler, I., additional, Hamadani, M., additional, Kline, J., additional, Mayer, J., additional, Savage, K. J., additional, Advani, R., additional, Caimi, P., additional, Casasnovas, R.-O., additional, Feldman, T., additional, Hess, B., additional, Bastos-Oreiro, M., additional, Iyengar, S., additional, Eisen, S., additional, Negievich, Y., additional, Wang, L., additional, Wuerthner, J., additional, and Herrera, A. F., additional

Published
2022
Full Text
View/download PDF

16. Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study

Author

Schuster, M. Zijlstra, J. Casasnovas, R.-O. Vermaat, J.S.P. Kalakonda, N. Goy, A. Choquet, S. Neste, E.V.D. Hill, B. Thieblemont, C. Cavallo, F. De la Cruz, F. Kuruvilla, J. Hamad, N. Jaeger, U. Caimi, P. Gurion, R. Warzocha, K. Bakhshi, S. Sancho, J.-M. Follows, G. Egyed, M. Offner, F. Vassilakopoulos, T. Samal, P. Ku, M. Ma, X. Corona, K. Chamoun, K. Shah, J. Shacham, S. Kauffman, M.G. Canales, M. Maerevoet, M.

Abstract

Background: Despite a number of treatment options, patients with diffuse large B-cell lymphoma (DLBCL) whose disease has become refractory to treatment have a poor prognosis. Selinexor is a novel, oral drug that is approved to treat patients with relapsed/refractory DLBCL. In this post hoc analysis of the SADAL study, a multinational, open-label study, we evaluated subpopulations to determine if response to single agent selinexor is impacted by number of lines of prior treatment, autologous stem cell transplant (ASCT), response to first and most recent therapies, and time to progressive disease. Patients: Patients (n = 134) with DLBCL after 2-5 prior therapies were enrolled in SADAL and received 60mg selinexor twice weekly. Results: The median overall survival was 9.0 months and median progression free survival was 2.6 months. Patients who had the best overall response rate (ORR) and disease control rate were those who had prior ASCT (42.5% and 50.0%) or responded to last line of therapy (35.9% and 43.5%). Patients with primary refractory DLBCL also showed responses (ORR 21.8%). Adverse events between subgroups were similar to the overall study population, the most common being thrombocytopenia (29.1%), fatigue (7.5%), and nausea (6.0%). Conclusion: Regardless of prior therapy and disease refractory status, selinexor treatment demonstrated results consistent with its novel mechanism of action and lack of cross-resistance. Thus, single agent oral selinexor can induce deep, durable, and tolerable responses in patients with DLBCL who have recurrent disease after several chemoimmunotherapy combination regimens. © 2021

Published
2022

19. Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma

Author

Shah, J. Shacham, S. Kauffman, M. Daniele, P. Tomaras, D. Tremblay, G. Casasnovas, R.-O. Maerevoet, M. Zijlstra, J. Follows, G. P Vermaat, J.S. Kalakonda, N. Goy, A.H. Choquet, S. Den Neste, E.V. Hill, B.T. Thieblemont, C. Cavallo, F. La Cruz, F.D. Kuruvilla, J. Hamad, N. Bouabdallah, R. Jäger, U. Caimi, P. Gurion, R. Warzocha, K. Bakhshi, S. Sancho, J.M. Schuster, M. Egyed, M. Offner, F. Vasilakopoulos, T.P. Samal, P. Nagy, A. Ku, M. Canales Albendea, M.Á.

Abstract

Aim: Evaluate health-related quality of life (HRQoL) and health utility impact of single-agent selinexor in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma. Patients & methods: Functional Assessment of Cancer Therapy (FACT)-Lymphoma and EuroQoL five-dimensions five-levels data collected in the single-arm Phase IIb trial SADAL (NCT02227251) were analyzed with mixed-effects models. Results: Treatment responders maintained higher FACT-Lymphoma (p ≤ 0.05), FACT-General (p < 0.05) and EuroQoL five-dimensions five-levels index scores (p < 0.001) beginning in cycle 3. The estimated difference in health state utilities for treatment response and progressive disease was both statistically significant and clinically meaningful (mean difference: 0.07; p = 0.001). Conclusion: In patients with relapsed/refractory diffuse large B-cell lymphoma, objective response to selinexor was associated with HRQoL maintenance, reduction in disease-related HRQoL decrements and higher health utilities. © 2021 Patrick Daniele.

Published
2021

20. Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study

Author

Maerevoet, M, Zijlstra, JM, Follows, G, Casasnovas, R-O, Vermaat, JSP, Kalakonda, N, Goy, A, Choquet, S, Van den Neste, E, Hill, B, Thieblemont, C, Cavallo, F, De la Cruz, F, Kuruvilla, J, Hamad, N, Jaeger, U, Caimi, P, Gurion, R, Warzocha, K, Bakhshi, S, Sancho, J-M, Schuster, M, Egyed, M, Offner, F, Vassilakopoulos, TP, Samal, P, Ku, M, Ma, X, Corona, K, Chamoun, K, Shah, J, Shacham, S, Kauffman, MG, Canales, M, Maerevoet, M, Zijlstra, JM, Follows, G, Casasnovas, R-O, Vermaat, JSP, Kalakonda, N, Goy, A, Choquet, S, Van den Neste, E, Hill, B, Thieblemont, C, Cavallo, F, De la Cruz, F, Kuruvilla, J, Hamad, N, Jaeger, U, Caimi, P, Gurion, R, Warzocha, K, Bakhshi, S, Sancho, J-M, Schuster, M, Egyed, M, Offner, F, Vassilakopoulos, TP, Samal, P, Ku, M, Ma, X, Corona, K, Chamoun, K, Shah, J, Shacham, S, Kauffman, MG, and Canales, M

Abstract

Patients with RR DLBCL who have received ≥ 2 lines of therapy have limited treatment options and an expected overall survival (OS) of < 6 months. The SADAL study evaluated single-agent oral selinexor in patients with RR DLBCL and demonstrated an overall response rate (ORR) of 29.1% with median duration of response (DOR) of 9.3 months. The analyses described here evaluated a number of subpopulations in order to understand how response correlates with survival outcomes in order to identify patients who could most optimally benefit from selinexor treatment. Median age was 67 years; 44.8% of patients were ≥ 70 years of age. The median OS was 9.0 months (95% CI 6.2, 13.7) at a median follow-up of 14.8 months. The median OS was not reached in patients with a CR or PR, while patients who did not respond have a median OS of 4.9 months (p < 0.0001). Patients < 70 years had an OS of 11.1 months compared with 7.8 months in patients ≥ 70 years. Among patients with or without prior ASCT, the median OS was 10.9 and 7.8 months, respectively. Among patients with disease refractory to the most recent DLBCL treatment regimen, the median OS was 7.0 months compared with 11.1 months for disease not refractory to the most recent treatment. In a patient population in which survival is expected to be < 6 months, treatment with single-agent oral selinexor was associated with a median survival of 9 months. Increased median OS observed in patients responding to selinexor was consistent across subgroups regardless of age, prior ASCT therapy, or refractory status. Randomized studies of selinexor in combination with a variety of other anti-DLBCL agents are planned. This trial was registered at ClinicalTrials.gov (NCT02227251) on August 28, 2014. https://clinicaltrials.gov/ct2/show/NCT02227251 .

Published
2021

21. Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma

Author

Shah, J, Shacham, S, Kauffman, M, Daniele, P, Tomaras, D, Tremblay, G, Casasnovas, R-O, Maerevoet, M, Zijlstra, J, Follows, G, Vermaat, JSP, Kalakonda, N, Goy, AH, Choquet, S, Van den Neste, E, Hill, BT, Thieblemont, C, Cavallo, F, de la Cruz, F, Kuruvilla, J, Hamad, N, Bouabdallah, R, Jager, U, Caimi, P, Gurion, R, Warzocha, K, Bakhshi, S, Sancho, JM, Schuster, M, Egyed, M, Offner, F, Vasilakopoulos, TP, Samal, P, Nagy, A, Ku, M, Canales Albendea, MA, Shah, J, Shacham, S, Kauffman, M, Daniele, P, Tomaras, D, Tremblay, G, Casasnovas, R-O, Maerevoet, M, Zijlstra, J, Follows, G, Vermaat, JSP, Kalakonda, N, Goy, AH, Choquet, S, Van den Neste, E, Hill, BT, Thieblemont, C, Cavallo, F, de la Cruz, F, Kuruvilla, J, Hamad, N, Bouabdallah, R, Jager, U, Caimi, P, Gurion, R, Warzocha, K, Bakhshi, S, Sancho, JM, Schuster, M, Egyed, M, Offner, F, Vasilakopoulos, TP, Samal, P, Nagy, A, Ku, M, and Canales Albendea, MA

Abstract

Aim: Evaluate health-related quality of life (HRQoL) and health utility impact of single-agent selinexor in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma. Patients & methods: Functional Assessment of Cancer Therapy (FACT) - Lymphoma and EuroQoL five-dimensions five-levels data collected in the single-arm Phase IIb trial SADAL (NCT02227251) were analyzed with mixed-effects models. Results: Treatment responders maintained higher FACT - Lymphoma (p ≤ 0.05), FACT - General (p < 0.05) and EuroQoL five-dimensions five-levels index scores (p < 0.001) beginning in cycle 3. The estimated difference in health state utilities for treatment response and progressive disease was both statistically significant and clinically meaningful (mean difference: 0.07; p = 0.001). Conclusion: In patients with relapsed/refractory diffuse large B-cell lymphoma, objective response to selinexor was associated with HRQoL maintenance, reduction in disease-related HRQoL decrements and higher health utilities.

Published
2021

22. PHASED VARIANTS IMPROVE DLBCL MINIMAL RESIDUAL DISEASE DETECTION AT THE END OF THERAPY

Author

Kurtz, D. M, primary, Chabon, J. J, additional, Soo, J, additional, Co Ting Keh, L, additional, Alig, S, additional, Schultz, A, additional, Jin, M. C, additional, Scherer, F, additional, Craig, A. F. M, additional, Liu, C. L, additional, Dührsen, U, additional, Hüttmann, A, additional, Casasnovas, R.‐O, additional, Westin, J. R, additional, Roschewski, M, additional, Wilson, W. H, additional, Gaidano, G, additional, Rossi, D, additional, Diehn, M, additional, and Alizadeh, A. A, additional

Published
2021
Full Text
View/download PDF

23. CIRCULATING TUMOR DNA LOAD AND TOTAL METABOLIC TUMOR VOLUME IN DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) PATIENTS TREATED BY R‐CHOP – FROM REMARC, A LYSA STUDY

Author

Bohers, E, primary, Delfau‐Larue, M, additional, Vercellino, L, additional, Cottereau, A, additional, Viennot, M, additional, Viailly, P, additional, Salles, G, additional, Tilly, H, additional, Damaj, G, additional, Haioun, C, additional, Ribrag, V, additional, Morschhauser, F, additional, Casasnovas, R, additional, Nicolas‐Virelizier, E, additional, Feugier, P, additional, Bouabdallah, R, additional, Cartron, G, additional, Renaud, L, additional, Chartier, L, additional, Portugues, C, additional, Meignan, M, additional, Jardin, F, additional, and Thieblemont, C, additional

Published
2021
Full Text
View/download PDF

24. PROGNOSTIC SCORING SYSTEMS FOR SEVERE CRS AND ICANS AFTER AUTOLOGOUS ANTI‐CD19 CAR T CELLS IN LARGE B‐CELL LYMPHOMA: A DESCAR‐T REGISTRY STUDY FORM THE LYSA.

Author

Sesques, P., Di blasi, R., Legouill, S., Cartron, G., Beauvais, D., Le Bras, F., Gros, F., Choquet, S., Bories, P., Rubio, M., Casasnovas, R., Bay, J., Mohty, M., Joris, M., Abraham, J., Llorente, C. Castilla, Loschi, M., Carras, S., Chauchet, A., and Gyan, E.

Subjects
T cells, CYTOKINE release syndrome, LYMPHOMAS
Abstract

PROGNOSTIC SCORING SYSTEMS FOR SEVERE CRS AND ICANS AFTER AUTOLOGOUS ANTI-CD19 CAR T CELLS IN LARGE B-CELL LYMPHOMA: A DESCAR-T REGISTRY STUDY FORM THE LYSA B Background: b Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are common immune-related toxicities associated with chimeric antigen receptor (CAR)-T-cell therapy. B S. Legouill b Honoraria: Janssen-Cilag, Kite/Gilead and Novartis B G. Cartron b Honoraria: Roche, Bristol Myers Squibb, Onwards Therapeutics, MedxCell, EmerCell, MabQ, Sanofi, Abbvie, Takeda, Roche, Janssen, Roche, Novartis and Myltenyi B D. Beauvais b Honoraria: Kite/Gilead B F. Gros b Honoraria: Bristol Myers Squibb, Novartis and Kite/Gilead B P. Bories b Honoraria: Bristol Myers Squibb, Kite/Gilead, Novartis and Abbvie B M. Rubio b Honoraria: Novartis and Kite/Gilead. [Extracted from the article]

Published
2023
Full Text
View/download PDF

27. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study

Author

Lefrère, F, Delmer, A, Suzan, F, Levy, V, Belanger, C, Djabarri, M, Arnulf, B, Damaj, G, Maillard, N, Ribrag, V, Janvier, M, Sebban, C, Casasnovas, R-O, Bouabdallah, R, Dreyfus, F, Verkarre, V, Delabesse, E, Valensi, F, McIntyre, E, Brousse, N, Varet, B, and Hermine, O

Published
2002
Full Text
View/download PDF

29. Alternating courses of 3x CHOP and 3x DHAP plus Rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) is superior to 6 courses CHOP plus Rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: Results of the MCL Younger Trial of the European mantle cell lymphoma network (MCL net): V116

Author

Unterhalt, M., Hoster, E., Ribrag, V., Walewski, J., Brousse, N., Thieblemont, C., Bouabdallah, R., Stilgenbauer, S., Feugier, P., Forstpointner, R., Haouin, C., Kneba, M., Hänel, M., Casasnovas, R. O., Finke, J., Hallek, M., Wandt, H., Bosly, A., Klapper, W., Gisselbrecht, C., Coiffier, B., Hiddemann, W., Dreyling, M., and Hermine, O.

Published
2011

30. Lymphomes malins non hodgkiniens

Author

Carli, P. M., primary, Monnereau, A., additional, Casasnovas, R. O., additional, Troussard, X., additional, Maarouf, N., additional, and Maynadié, M., additional

Published
2007
Full Text
View/download PDF

32. Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

Author

Morschhauser F, Fowler N, Feugier P, Bouabdallah R, Tilly H, Palomba M, Fruchart C, Libby E, Casasnovas R, Flinn I, Haioun C, Maisonneuve H, Ysebaert L, Bartlett N, Bouabdallah K, Brice P, Ribrag V, Daguindau N, Le Gouill S, Pica G, Garcia-Sancho A, Lopez-Guillermo A, Larouche J, Ando K, da Silva M, Andre M, Zachee P, Sehn L, Tobinai K, Cartron G, Liu D, Wang J, Xerri L, Salles G, and RELEVANCE Trial Investigators

Published
2018

35. Prognosis value of baseline total metabolic tumor volume (TMTV) in advanced Hodgkin lymphoma (HL) : Ancillary study of AHL2011 LYSA trial

Author

Kanoun, S., Berriolo-Riedinger, A., Tal, I., Edeline, V., Cottereau, A., Brice, P., Bouabdallah, R., Gilles Salles, Stamatoullas, A., Dupuis, J., Andre, M., Mounier, N., Ferme, C., Meignan, M., Casasnovas, R., Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Laboratoire Electronique, Informatique et Image ( Le2i ), Université de Bourgogne ( UB ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Centre National de la Recherche Scientifique ( CNRS ), Centre Régional de Lutte contre le cancer - Centre Georges-François Leclerc ( CRLCC - CGFL ), Beth Israel Deaconess Medical Center [Boston, USA], Harvard Medical School [Boston] ( HMS ), Institut Curie, Hôpital Henri Mondor, Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Hôpital Saint-Louis, Assistance publique - Hôpitaux de Paris (AP-HP)-Université Paris Diderot - Paris 7 ( UPD7 ), Institut Paoli Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), CHU Lyon, Hospices Civils de Lyon ( HCL ), CRLCC Henri Becquerel, CHU Henri Mondor, Cliniques Universitaires UCL Mont-Godinne, Hôpital l'Archet, Institut Gustave Roussy ( IGR ), Sponsor(s):European Assoc Nucl Med, European-Association-of-Nuclear-Medicine (EANM), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Laboratoire Electronique, Informatique et Image [UMR6306] (Le2i), Université de Bourgogne (UB)-École Nationale Supérieure d'Arts et Métiers (ENSAM), Arts et Métiers Sciences et Technologies, HESAM Université (HESAM)-HESAM Université (HESAM)-Arts et Métiers Sciences et Technologies, HESAM Université (HESAM)-HESAM Université (HESAM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Centre National de la Recherche Scientifique (CNRS), Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER, Harvard Medical School [Boston] (HMS), Institut Curie [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Paoli-Calmettes, Hospices Civils de Lyon (HCL), Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Institut Gustave Roussy (IGR), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), université de Bourgogne, LE2I, HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Arts et Métiers Sciences et Technologies, and HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Centre National de la Recherche Scientifique (CNRS)

Subjects
[SDV.IB] Life Sciences [q-bio]/Bioengineering, [SDV.IB.IMA] Life Sciences [q-bio]/Bioengineering/Imaging, [SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imaging, [SDV.IB]Life Sciences [q-bio]/Bioengineering, [SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicine, [ SDV.IB ] Life Sciences [q-bio]/Bioengineering, ComputingMilieux_MISCELLANEOUS, [ SDV.IB.IMA ] Life Sciences [q-bio]/Bioengineering/Imaging, [SDV.IB.MN] Life Sciences [q-bio]/Bioengineering/Nuclear medicine, [ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicine
Abstract

International audience

Published
2016

36. REMARC STUDY: CORRELATION OF LYMPHOMA PD AND DEATH AND HEALTH-RELATED QOL WITH MAINTENANCE LENALIDOMIDE VS PLACEBO IN ELDERLY DLBCL PATIENT RESPONDERS TO R-CHOP

Author

Thieblemont, C., primary, Casasnovas, R., additional, Mounier, N., additional, Perrot, A., additional, Morschhauser, F., additional, Tilly, H., additional, Fruchart, C., additional, Corront, B., additional, Haouin, C., additional, Van Eygen, K., additional, Obéric, L., additional, Bouabdallah, R., additional, Sebban, C., additional, Bordessoule, D., additional, Fitoussi, O., additional, Van Hoof, A., additional, Eisenmann, J.C., additional, Lionne-Huyghe, P., additional, Deeren, D., additional, Gomes Da Silva, M., additional, Trotman, J., additional, Grosicki, S., additional, Greil, R., additional, Caballero, D., additional, and Coiffier, B., additional

Published
2017
Full Text
View/download PDF

37. PROGNOSTIC MODEL FOR HIGH TUMOR BURDEN FOLLICULAR LYMPHOMA INCLUDING BASELINE TOTAL METABOLIC TUMOR VOLUME AND END INDUCTION PET: a POOLED ANALYSIS FROM LYSA AND FIL TRIALS

Author

Cottereau, A., primary, Versari, A., additional, Dupuis, J., additional, Chartier, L., additional, Menga, M., additional, Casasnovas, R., additional, Haioun, C., additional, Tilly, H., additional, Tarantino, V., additional, Dubreuil, J., additional, Federico, M., additional, Salles, G., additional, Luminari, S., additional, Trotman, J., additional, and Meignan, M., additional

Published
2017
Full Text
View/download PDF

38. A PHASE 2B RANDOMIZED STUDY OF SINGLE AGENT SELINEXOR IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

Author

Casasnovas, R., primary, Westin, J., additional, Thieblemont, C., additional, Zijlstra, J., additional, Hill, B., additional, De La Cruz Vicente, F., additional, Choquet, S., additional, Caimi, P., additional, Kaplan, J., additional, Canales, M., additional, Kuruvilla, J., additional, Follows, G., additional, van den Neste, E., additional, Meade, J., additional, Wrigley, B., additional, Devlin, M., additional, Saint-Martin, J., additional, Nippgen, C., additional, Gardner, H., additional, Shacham, S., additional, Kauffman, M., additional, and Maerevoet, M., additional

Published
2017
Full Text
View/download PDF

39. PROGNOSTIC VALUE OF BASELINE TOTAL METABOLIC TUMOR VOLUME (TMTV) FOR PATIENTS WITH EARLY STAGE HODGKIN LYMPHOMA ENROLLED IN THE STANDARD ARM OF THE H10 (EORTC/LYSA/FIL) TRIAL

Author

Cottereau, A., primary, Versari, A., additional, Loft, A., additional, Casasnovas, R., additional, Bellei, M., additional, Ricci, R., additional, Bardet, S., additional, Castagnoli, A., additional, Brice, P., additional, Raemaekers, J., additional, Deau, B., additional, Fortpied, C., additional, Raveloarivahy, T., additional, Girinsky, T., additional, Van Zele, E., additional, Vander Borght, T., additional, Federico, M., additional, Hutchings, M., additional, Ricardi, U., additional, Andre, M., additional, and Meignan, M., additional

Published
2017
Full Text
View/download PDF

40. LOW NK CELL COUNT AT DIAGNOSIS IS ASSOCIATED WITH SHORTER PFS IN ELDERLY PATIENTS WITH DLBCL TREATED WITH RCHOP AND RANDOMIZED FOR LENALIDOMIDE MAINTENANCE: a LYSA STUDY

Author

Delfau-Larue, M.H., primary, Beldi-Ferchiou, A., additional, Jais, J., additional, Godard, N., additional, Salles, G.A., additional, Casasnovas, R., additional, Tilly, H., additional, Fruchart, C., additional, Morschhauser, F., additional, Haioun, C., additional, Lazarovici, J., additional, Perrot, A., additional, Sebban, C., additional, Bouabdallah, R., additional, Gonzalez, H., additional, Corront, B., additional, Oberic, L., additional, Briere, J., additional, Gaulard, P., additional, Coiffier, B., additional, and Thieblemont, C., additional

Published
2017
Full Text
View/download PDF

41. ROMIDEPSIN PLUS CHOP VERSUS CHOP IN PATIENTS WITH PREVIOUSLY UNTREATED PERIPHERAL T‐CELL LYMPHOMA: FINAL ANALYSIS OF THE RO‐CHOP TRIAL.

Author

Camus, V., Thieblemont, C., Gaulard, P., Cheminant, M., Casasnovas, R., Ysebaert, L., Damaj, G. L., Guidez, S., Pica, G. M., Kim, W. S., Lim, S. T., Andre, M., Gutiérrez, N., Penarrubia, M. J., Staber, P. B., Trotman, J., Hüttmann, A., Stefoni, V., Rossi, G., and Delfau‐Larue, M.

Subjects
T-cell lymphoma, STEM cell transplantation
Abstract

B Introduction: b The primary analysis of the Ro-CHOP trial ( I NCT01796002 i ) demonstrated that romidepsine (Ro) plus CHOP did not provide an increased efficacy compared with CHOP alone in patients with previously untreated peripheral T-cell lymphoma (PTCL). ROMIDEPSIN PLUS CHOP VERSUS CHOP IN PATIENTS WITH PREVIOUSLY UNTREATED PERIPHERAL T-CELL LYMPHOMA: FINAL ANALYSIS OF THE RO-CHOP TRIAL B Methods: b The study was an open-label multicenter randomized (1:1) phase III study of Ro-CHOP versus CHOP as frontline treatment of patients 18-80 years with PTCL. [Extracted from the article]

Published
2023
Full Text
View/download PDF

43. Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II lymphoma study Association trial

Author

UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Mounier, N., El Gnaoui, T., Tilly, H., Canioni, D., Sebban, C., Casasnovas, R.-O., Delarue, R., Sonet, Anne, Beaussart, P., Petrella, T., Castaigne, S., Bologna, S., Salles, G., Rahmouni, A., Gaulard, P., Haioun, C., UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Mounier, N., El Gnaoui, T., Tilly, H., Canioni, D., Sebban, C., Casasnovas, R.-O., Delarue, R., Sonet, Anne, Beaussart, P., Petrella, T., Castaigne, S., Bologna, S., Salles, G., Rahmouni, A., Gaulard, P., and Haioun, C.

Abstract

A previous pilot study with rituximab, gemcitabine and oxaliplatin showed promising activity in patients with refractory/relapsed B-cell lymphoma. We, therefore, conducted a phase II study to determine whether these results could be reproduced in a multi-institutional setting. This phase II study included 49 patients with refractory (n=6) or relapsing (n=43) diffuse large B-cell lymphoma. The median age of the patients was 69 years. Prior treatment included rituximab in 31 (63%) and autologous transplantation in 17 (35%) patients. International Prognostic Index at enrollment was >2 in 34 patients (71%). The primary endpoint was overall response rate after four cycles of treatment. Patients were planned to receive eight cycles if they reached at least partial remission after four cycles. After four cycles 21 patients (44%) were in complete remission and 8 (17%) in partial remission, resulting in an overall response rate of 61%. Factors significantly affecting overall response rate were early (<1 year) progression/relapse (18% versus 54%; P=0.001) and prior exposure to rituximab (23% versus 65%; P=0.004). Five-year progression-free and overall survival rates were 12.8% and 13.9%, respectively. Rituximab, gemcitabine and oxaliplatin were well tolerated with grade 3-4 infectious episodes in 22% of the cycles. These results are the first confirmation from a multicenter study that rituximab, gemcitabine and oxaliplatin provide a consistent response rate in patients with refractory/relapsed diffuse large B-cell lymphoma. This therapy can now be considered as a platform for new combinations with targeted treatments. This trial was registered at clinicaltrial.gov under #NCT00169195. © 2013 Ferrata Storti Foundation.

Published
2013

44. Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial

Author

Mounier, N., primary, El Gnaoui, T., additional, Tilly, H., additional, Canioni, D., additional, Sebban, C., additional, Casasnovas, R.-O., additional, Delarue, R., additional, Sonet, A., additional, Beaussart, P., additional, Petrella, T., additional, Castaigne, S., additional, Bologna, S., additional, Salles, G., additional, Rahmouni, A., additional, Gaulard, P., additional, and Haioun, C., additional

Published
2013
Full Text
View/download PDF

45. Isodesmic reaction for accurate theoretical pKa calculations of amino acids and peptides.

Author

Sastre, S., Casasnovas, R., Muñoz, F., and Frau, J.

Abstract

Theoretical and quantitative prediction of pKa values at low computational cost is a current challenge in computational chemistry. We report that the isodesmic reaction scheme provides semi-quantitative predictions (i.e. mean absolute errors of 0.5–1.0 pKa unit) for the pKa1 (α-carboxyl), pKa2 (α-amino) and pKa3 (sidechain groups) of a broad set of amino acids and peptides. This method fills the gaps of thermodynamic cycles for the computational pKa calculation of molecules that are unstable in the gas phase or undergo proton transfer reactions or large conformational changes from solution to the gas phase. We also report the key criteria to choose a reference species to make accurate predictions. This method is computationally inexpensive and makes use of standard density functional theory (DFT) and continuum solvent models. It is also conceptually simple and easy to use for researchers not specialized in theoretical chemistry methods. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

49. Follicular large-cell lymphoma treated with intensive chemotherapy: an analysis of 89 cases included in the LNH87 trial and comparison with the outcome of diffuse large B-cell lymphoma. Groupe d'Etude des Lymphomes de l'Adulte.

Author

Wendum, D, primary, Sebban, C, additional, Gaulard, P, additional, Coiffier, B, additional, Tilly, H, additional, Cazals, D, additional, Boehn, A, additional, Casasnovas, R O, additional, Bouabdallah, R, additional, Jaubert, J, additional, Ferrant, A, additional, Diebold, J, additional, de Mascarel, A, additional, and Gisselbrecht, C, additional

Published
1997
Full Text
View/download PDF

50. Phase III multicentric randomized study of quinine as a potential MDR reversing agent in acute leukemias

Author

Solary, E, primary, Quiquandon, I, additional, Moreau, P, additional, Witz, B, additional, Casasnovas, R O, additional, Genne, P, additional, Cahn, J Y, additional, Sadoun, A, additional, Pignon, B, additional, Berthou, C, additional, Maloisel, F, additional, Guyotat, D, additional, Casassus, P, additional, Gardembas, M, additional, Lamy, Y, additional, Audhuy, B, additional, and Colombat, P, additional

Published
1994
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results